TY  - GEN
AU  - Attal,Michel
AU  - Richardson,Paul G
AU  - Rajkumar,S Vincent
AU  - San-Miguel,Jesus
AU  - Beksac,Meral
AU  - Spicka,Ivan
AU  - Leleu,Xavier
AU  - Schjesvold,Fredrik
AU  - Moreau,Philippe
AU  - Dimopoulos,Meletios A
AU  - Huang,Jeffrey Shang-Yi
AU  - Minarik,Jiri
AU  - Cavo,Michele
AU  - Prince,H Miles
AU  - Macé,Sandrine
AU  - Corzo,Kathryn P
AU  - Campana,Frank
AU  - Le-Guennec,Solenn
AU  - Dubin,Franck
AU  - Anderson,Kenneth C
TI  - Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
SN  - 1474-547X
PY  - 2020///0106
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Asia
KW  - Dexamethasone
KW  - Europe
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Recurrence, Local
KW  - North America
KW  - Progression-Free Survival
KW  - Thalidomide
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Video-Audio Media
UR  - https://doi.org/10.1016/S0140-6736(19)32556-5
ER  -